

Rivaroxaban for Stroke Prevention in East Asian Patients

Stroke

45, 1739-1747

DOI: [10.1161/strokeaha.113.002968](https://doi.org/10.1161/strokeaha.113.002968)

Citation Report

#	ARTICLE	IF	CITATIONS
1	XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. <i>Vascular Health and Risk Management</i> , 2014, 10, 425.	1.0	29
2	Stroke Prevention in Asian Patients With Atrial Fibrillation. <i>Stroke</i> , 2014, 45, 1608-1609.	1.0	12
3	Treatment of atrial fibrillation in East Asia: What is perception and what is reality?. <i>Heart Rhythm</i> , 2014, 11, 1409-1410.	0.3	0
4	Impact of Non-Vitamin K Antagonist Oral Anticoagulants on Intracranial Bleeding in Asian Patients With Non-Valvular Atrial Fibrillation. <i>Circulation Journal</i> , 2014, 78, 2367-2372.	0.7	46
5	Stroke prevention with rivaroxaban in higher-risk populations with atrial fibrillation. <i>International Journal of Clinical Practice</i> , 2015, 69, 743-756.	0.8	9
6	Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1606-1614.	1.9	44
7	Effect of Renal Function on Anticoagulation Therapy in Asian Patients. <i>Circulation Journal</i> , 2015, 79, 2098-2099.	0.7	6
8	Comparison of the Efficacy and Safety of Oral Anticoagulants in East Asians With Atrial Fibrillation. <i>Circulation Journal</i> , 2015, 79, 2537-2538.	0.7	0
9	The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society. <i>Korean Circulation Journal</i> , 2015, 45, 9.	0.7	34
10	New Insights into Nonvitamin K Antagonist Oral Anticoagulants' Reversal of Intracerebral Hemorrhage. <i>Frontiers of Neurology and Neuroscience</i> , 2016, 37, 93-106.	3.0	5
11	Asian strategy for stroke prevention in atrial fibrillation. <i>Europace</i> , 2015, 17, ii31-ii39.	0.7	36
12	Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal. <i>International Journal of Cardiology</i> , 2015, 180, 246-254.	0.8	141
13	Acute Reperfusion Therapy and Stroke Care in Asia After Successful Endovascular Trials. <i>Stroke</i> , 2015, 46, 1474-1481.	1.0	64
14	INR optimization based on stroke risk factors in patients with non-valvular atrial fibrillation. <i>International Journal of Clinical Pharmacy</i> , 2015, 37, 1038-1046.	1.0	4
15	Antithrombotic treatment for stroke prevention in atrial fibrillation: The Asian agenda. <i>International Journal of Cardiology</i> , 2015, 191, 244-253.	0.8	25
16	Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 2555-2561.	1.0	189
17	Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1339-1347.	1.2	104
18	Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation. <i>Tohoku Journal of Experimental Medicine</i> , 2016, 240, 259-268.	0.5	12

#	ARTICLE	IF	CITATIONS
19	Has the Safety of Edoxaban 60 mg Among East Asian Atrial Fibrillation Patients Been Truly Proven by the ENGAGE AF-TIMI 48 Subanalysis?â€œâ€“ Reply â€œ. Circulation Journal, 2016, 80, 2057.	0.7	0
20	2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. Journal of the Formosan Medical Association, 2016, 115, 893-952.	0.8	113
21	Standard dose versus low dose nonâ€œvitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of contemporary randomized controlled trials. Heart Rhythm, 2016, 13, 2340-2347.	0.3	25
22	Stroke Prediction in Atrial Fibrillation. Journal of the American College of Cardiology, 2016, 68, 471-472.	1.2	1
23	Modelling the cost-effectiveness of pharmacist-managed anticoagulation service for older adults with atrial fibrillation in Singapore. International Journal of Clinical Pharmacy, 2016, 38, 1230-1240.	1.0	8
24	Characteristics and Risk Factors for Type 2 Endoleak in an East Asian Population From a Japanese Multicenter Database. Circulation Journal, 2016, 80, 118-123.	0.7	19
25	Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillationâ€œâ€“ An ENGAGE AF-TIMI 48 Subanalysis â€œ. Circulation Journal, 2016, 80, 860-869.	0.7	83
26	Regional Differences in Frequency of Warfarin Therapy and Thromboembolism in Japanese Patients With Non-Valvular Atrial Fibrillationâ€œâ€“ Analysis of the J-RHYTHM Registry â€œ. Circulation Journal, 2016, 80, 1548-1555.	0.7	7
27	Regional Differences in Warfarin Therapy Among Japanese Patients With Atrial Fibrillation. Circulation Journal, 2016, 80, 1520-1522.	0.7	1
28	Has the Safety of Edoxaban 60 mg Among East Asian Atrial Fibrillation Patients Been Truly Proven by the ENGAGE AF-TIMI 48 Subanalysis?. Circulation Journal, 2016, 80, 2056.	0.7	0
29	Validation of a Modified CHA ₂ DS ₂ -VASc Score for Stroke Risk Stratification in Asian Patients With Atrial Fibrillation. Stroke, 2016, 47, 2462-2469.	1.0	78
30	Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation. Journal of the American College of Cardiology, 2016, 68, 1389-1401.	1.2	148
31	The Reality of â€œReal-Worldâ€œ Data. Journal of the American College of Cardiology, 2016, 68, 1402-1403.	1.2	4
33	Time in Therapeutic Range and Percentage of International Normalized Ratio in the Therapeutic Range as a Measure of Quality of Anticoagulation Control in Patients With Atrial Fibrillation. Canadian Journal of Cardiology, 2016, 32, 1247.e23-1247.e28.	0.8	23
34	Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent,) Tj ETQq0 0 0 rgBT /Overlock 10 Study. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 1342-1348.	0.7	13
35	Atrial Fibrillation and Stroke. Cardiology Clinics, 2016, 34, 317-328.	0.9	7
36	Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial. Thrombosis Research, 2017, 156, 184-190.	0.8	11
37	Epidemiology of Atrial Fibrillation: The Australian and Asia-Pacific Perspective. Heart Lung and Circulation, 2017, 26, 870-879.	0.2	74

#	ARTICLE	IF	CITATIONS
38	Volume and Characteristics of Intracerebral Hemorrhage with Direct Oral Anticoagulants in Comparison with Warfarin. <i>Cerebrovascular Diseases Extra</i> , 2017, 7, 62-71.	0.5	31
39	2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. <i>Journal of Arrhythmia</i> , 2017, 33, 345-367.	0.5	141
40	Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 549-560.	0.6	4
41	Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. <i>The Cochrane Library</i> , 2017, 2017, CD011373.	1.5	68
42	Once- or twice-daily non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of randomized controlled trials. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 591-598.	0.8	8
44	Special considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation. <i>Clinical Cardiology</i> , 2017, 40, 126-131.	0.7	21
45	Intracranial Bleeding. , 2017, , 25-39.		0
46	Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2017, 11, 105-120.	1.0	10
47	Rationale and design of ASSAF (A study of the safety and efficacy of anticoagulant therapy in the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.5	1
48	Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice: Focus on Rivaroxaban in Stroke Prevention in Patients With Atrial Fibrillation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 711-724.	0.7	2
49	Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study. <i>Scientific Reports</i> , 2018, 8, 3451.	1.6	23
50	Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	113
51	Efficacy and Safety Outcomes of Direct Oral Anticoagulants and Amiodarone in Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2018, 131, 573.e1-573.e8.	0.6	19
52	Fitting the right non-vitamin K antagonist oral anticoagulant to the right patient with non-valvular atrial fibrillation: an evidence-based choice. <i>Annals of Medicine</i> , 2018, 50, 288-302.	1.5	10
53	The Taiwan Heart Registries. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1273-1283.	1.2	32
54	Drug Class, Renal Elimination, and Outcomes of Direct Oral Anticoagulants in Asian Patients: A Meta-Analysis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 857-864.	0.7	4
55	Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non-Vitamin K Antagonist Oral Anticoagulants. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1503-1519.	1.4	11
56	FXa Direct Synthetic Inhibitors. , 0, , .		3

#	ARTICLE	IF	CITATIONS
57	XANAP: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia. <i>Journal of Arrhythmia</i> , 2018, 34, 418-427.	0.5	20
58	Anticoagulation Resumption After Intracerebral Hemorrhage. <i>Current Atherosclerosis Reports</i> , 2018, 20, 32.	2.0	41
59	Global Prospective Safety Analysis of Rivaroxaban. <i>Journal of the American College of Cardiology</i> , 2018, 72, 141-153.	1.2	48
60	Stroke Prevention in Atrial Fibrillation: Focus on Asian Patients. <i>Korean Circulation Journal</i> , 2018, 48, 665.	0.7	44
61	The Use of Direct Oral Anticoagulants for Prevention of Stroke and Systemic Embolic Events in East Asian Patients with Nonvalvular Atrial Fibrillation. <i>Cardiovascular Innovations and Applications</i> , 2018, 3, .	0.1	0
62	Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2019, 54, 73-80.	0.6	4
63	Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Asians With Atrial Fibrillation. <i>Stroke</i> , 2019, 50, 2819-2828.	1.0	28
64	Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or ROKET AF Trials) in Asian Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2019, 8, e013053.	1.6	19
65	Adverse reaction profiles of hemorrhagic adverse reactions caused by direct oral anticoagulants analyzed using the Food and Drug Administration Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) database. <i>International Journal of Medical Sciences</i> , 2019, 16, 1295-1303.	1.1	22
66	Comparative Effectiveness and Safety of Rivaroxaban in Adults With Nonvalvular Atrial Fibrillation. <i>American Journal of Therapeutics</i> , 2019, 26, e679-e703.	0.5	4
67	Guidelines for Atrial Fibrillation Treatment to Avoid Stroke Should Be Established for Each Region/Ethnicity. <i>Circulation Journal</i> , 2019, 83, 2413-2415.	0.7	1
68	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asians With Nonvalvular Atrial Fibrillation: A Network Meta-Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961988518.	0.7	4
69	Racial and Ethnic Differences in Response to Anticoagulation: A Review of the Literature. <i>Journal of Pharmacy Practice</i> , 2019, 34, 089719001989414.	0.5	13
70	Outcome of Anticoagulation Therapy of Left Atrial Thrombus or Sludge in Patients With Nonvalvular Atrial Fibrillation or Flutter. <i>American Journal of the Medical Sciences</i> , 2019, 358, 273-278.	0.4	4
71	Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2019, 40, 1518-1527.	1.0	67
72	Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 815-820.	0.7	19
73	Risk of intracerebral haemorrhage in Chinese patients with atrial fibrillation on warfarin with cerebral microbleeds: the IPAAC-Warfarin study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 428-435.	0.9	14
74	Intracerebral hemorrhage associated with warfarin versus non-vitamin K antagonist oral anticoagulants in Asian patients. <i>Journal of Clinical Neuroscience</i> , 2019, 61, 160-165.	0.8	10

#	ARTICLE	IF	CITATIONS
75	Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities. <i>European Heart Journal</i> , 2019, 40, 1504-1514.	1.0	64
76	Outcomes of intraparenchymal hemorrhage after direct oral anticoagulant or vitamin K antagonist therapy: A systematic review and meta-analysis. <i>Journal of Clinical Neuroscience</i> , 2019, 62, 188-194.	0.8	1
77	Stroke prevention in AF: Of Asians and non-Asians. <i>European Heart Journal</i> , 2019, 40, 1528-1530.	1.0	3
78	Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding. <i>Pharmacoeconomics</i> , 2019, 37, 279-289.	1.7	14
79	Factors That Affect Time to Switch From Warfarin to a Direct Oral Anticoagulant After Change in the Reimbursement Criteria in Patients With Atrial Fibrillation. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 57-64.	1.0	5
80	Clinical benefits and risks of antithrombotic therapy in patients with atrial fibrillation with comorbidities – A report from the CHART-2 Study. <i>International Journal of Cardiology</i> , 2020, 299, 160-168.	0.8	4
81	Combination of Oral Anticoagulants and Single Antiplatelets versus Triple Therapy in Nonvalvular Atrial Fibrillation and Acute Coronary Syndrome: Stroke Prevention among Asians. <i>International Journal of Angiology</i> , 2020, 29, 088-097.	0.2	3
82	Changing Treatment Patterns in Patients With Venous Thromboembolism in Taiwan. <i>Circulation Journal</i> , 2020, 84, 283-293.	0.7	6
83	The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation. <i>Medicine (United States)</i> , 2020, 99, e21025.	0.4	7
84	Effectiveness and Safety of Off-label Dosing of Non-vitamin K Antagonist Anticoagulant for Atrial Fibrillation in Asian Patients. <i>Scientific Reports</i> , 2020, 10, 1801.	1.6	33
85	Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Who are Indicated for Standard Dosing. <i>American Journal of Cardiology</i> , 2020, 125, 1332-1338.	0.7	35
86	Lower versus Standard INR Targets in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Thrombosis and Haemostasis</i> , 2020, 120, 484-494.	1.8	22
87	Age threshold for anticoagulation in patients with atrial fibrillation: A Swedish nationwide observational study. <i>International Journal of Cardiology</i> , 2021, 326, 92-97.	0.8	1
88	Prescriber compliance to direct oral anticoagulant labels and impact on outcomes in Thailand. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1390-1400.	1.1	7
89	Body Mass Index and Clinical Outcomes in Asian Patients With Atrial Fibrillation Receiving Oral Anticoagulation. <i>Stroke</i> , 2021, 52, 521-530.	1.0	18
90	Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism. <i>JAMA Network Open</i> , 2021, 4, e2036304.	2.8	24
91	Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. <i>Open Heart</i> , 2021, 8, e001471.	0.9	7
92	Comparison of non-vitamin K antagonist oral anticoagulants and well-controlled warfarin in octogenarians with non-valvular atrial fibrillation: Real-world data from a single tertiary center. <i>Anatolian Journal of Cardiology</i> , 2021, 25, 462-467.	0.5	0

#	ARTICLE	IF	CITATIONS
93	Effects of anti-thrombotic drugs on all-cause mortality after upper gastrointestinal bleeding in Japan: A multicenter study with 2205 cases. <i>Digestive Endoscopy</i> , 2021, , .	1.3	5
94	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , 2021, 23, 1612-1676.	0.7	494
95	Benefits and Harms of Low-Dose Rivaroxaban in Asian Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis of Real-World Studies. <i>Frontiers in Pharmacology</i> , 2021, 12, 642907.	1.6	7
96	Single direct oral anticoagulant therapy in stable patients with atrial fibrillation beyond 1 year after coronary stent implantation. <i>Heart</i> , 2022, 108, 285-291.	1.2	8
97	Can clinical pharmacists utilize telehealth to double the safety and efficacy of oral anticoagulation while reducing health care costs and improving patient satisfaction in patients with atrial fibrillation?. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 969-977.	0.5	0
98	Rivaroxaban: striking two birds with one stone. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 842-844.	0.7	0
99	Real-world comparison of non-vitamin K antagonist oral anticoagulants and warfarin in Asian octogenarian patients with atrial fibrillation. <i>Journal of Geriatric Cardiology</i> , 2016, 13, 566-72.	0.2	15
100	Surfing the Blood Coagulation Cascade: Insight into the Vital Factor Xa. <i>Current Medicinal Chemistry</i> , 2019, 26, 3175-3200.	1.2	17
101	A Prospective, Observational Study of Rivaroxaban For Stroke Prevention In Atrial Fibrillation â€” The XANAP Korea. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 906-913.	0.7	2
102	Asian Patients with Stroke plus Atrial Fibrillation and the Dose of Non-Vitamin K Oral Anticoagulants. <i>Journal of Stroke</i> , 2016, 18, 169-178.	1.4	16
103	Cost-Effectiveness Analysis of Oral Anticoagulants in Stroke Prevention among Patients with Atrial Fibrillation in Taiwan. <i>Acta Cardiologica Sinica</i> , 2020, 36, 50-61.	0.1	9
104	Efficacy and Safety of Direct Oral Anticoagulants in Patients with Diabetes and Nonvalvular Atrial Fibrillation: Meta-Analysis of Observational Studies. <i>Cardiovascular Therapeutics</i> , 2021, 2021, 1-14.	1.1	4
105	Prediction of recurrent stroke among ischemic stroke patients with atrial fibrillation: Development and validation of a risk score model. <i>PLoS ONE</i> , 2021, 16, e0258377.	1.1	3
106	Clinical development of novel oral anticoagulant (NOAC), Rivaroxaban. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2015, 26, 385-395.	0.1	0
107	Lights and shadows of NOAC international trialsâ€”the fruits and future seeds. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2015, 26, 410-419.	0.1	0
108	Early Experience of New Oral Anticoagulants for Stroke Prevention in Octogenarian Patients with Atrial Fibrillation. <i>Arrhythmia</i> , 2015, 16, 184-192.	0.0	0
109	NOAC in Asian. <i>International Journal of Arrhythmia</i> , 2016, 17, 32-35.	0.3	0
111	Real-world outcomes of anticoagulant prescription in anticoagulant-naïve octogenarian patients with non-valvular atrial fibrillation. <i>Journal of Cardiovascular Medicine and Cardiology</i> , 2020, , 188-194.	0.1	0

#	ARTICLE	IF	CITATIONS
112	Outcomes of Direct Oral Anticoagulants Co-Prescribed with Common Interacting Medications. <i>American Journal of Cardiology</i> , 2022, 162, 80-85.	0.7	3
113	Cost-effectiveness of anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation in mainland China. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 523-530.	0.7	11
114	Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice. <i>Journal of Clinical Medicine</i> , 2021, 10, 5337.	1.0	2
115	Long-term outcomes of percutaneous left atrial appendage closure for the prevention of stroke in patients with atrial fibrillation: Asia-Pacific experience. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1442-1449.	0.8	8
116	What is Standard Dose of Rivaroxaban in Elderly Asian Patients with Atrial Fibrillation: 20ms versus. 15mg?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110611.	0.7	4
117	Comparison of Different Dosages of Alteplase in Atrial Fibrillation-Related Acute Ischemic Stroke After Intravenous Thrombolysis: A Nationwide, Multicenter, Prospective Cohort Study in Taiwan. <i>Journal of the American Heart Association</i> , 2022, 11, e023032.	1.6	5
118	A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 803233.	1.1	0
119	Plasma Rivaroxaban Level in Patients With Early Stages of Chronic Kidney Disease Relationships With Renal Function and Clinical Events. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	4
120	XaMINA: A Real-World, Prospective, Observational Study of Treatment-Naïve Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia. <i>Advances in Therapy</i> , 0, , .	1.3	0
121	Rationale and design of a prospective study evaluating population pharmacokinetics and pharmacodynamics of rivaroxaban in Chinese patients with non-valvular atrial fibrillation. <i>BMJ Open</i> , 2022, 12, e058378.	0.8	1
122	Effect of Dronedarone in the Treatment of Atrial Fibrillation in the Asian Population: Post Hoc Analysis of the ATHENA Trial. <i>Clinical Therapeutics</i> , 2022, , , .	1.1	1
123	Stroke Prevention in Atrial Fibrillation. <i>JACC Asia</i> , 2022, 2, 395-411.	0.5	8
124	Stroke Prevention in Atrial Fibrillation. <i>JACC Asia</i> , 2022, 2, 519-537.	0.5	3
125	Association between concurrent use of diltiazem and DOACs and risk of bleeding in atrial fibrillation patients. <i>Journal of Interventional Cardiac Electrophysiology</i> , 0, , .	0.6	0
126	Safety and efficacy of combined antiplatelet and low-dose rivaroxaban in patients with chronic limb threatening ischaemia in Singapore. <i>Annals of the Academy of Medicine, Singapore</i> , 2022, 51, 580-582.	0.2	0
127	Impact of Concomitant Fluconazole on Direct Oral Anticoagulant Bleeding Risk. <i>Pharmacotherapy</i> , 0, , .	1.2	2
128	Association Between Concurrent Use of Amiodarone and DOACs and Risk of Bleeding in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2023, 186, 58-65.	0.7	3
129	Thrombosis and anticoagulation: clinical issues of special importance to hematologists who practice in Asia. <i>Hematology American Society of Hematology Education Program</i> , 2022, 2022, 474-480.	0.9	4

#	ARTICLE	IF	CITATIONS
130	Comparison of Efficacy and Safety of Direct Oral Anticoagulants and Warfarin between Patients in Asian and Non-Asian Regions: A Systematic Review and Meta-Regression Analysis. Clinical Pharmacology and Therapeutics, 2023, 113, 1240-1250.	2.3	2